| 3.29 -0.09 (-2.66%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.47 |
1-year : | 4.98 |
| Resists | First : | 3.83 |
Second : | 4.26 |
| Pivot price | 3.54 |
|||
| Supports | First : | 3.11 | Second : | 2.59 |
| MAs | MA(5) : | 3.31 |
MA(20) : | 3.58 |
| MA(100) : | 3.92 |
MA(250) : | 3.81  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.7 |
D(3) : | 24.8 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 5.05 | Low : | 2.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IVA ] has closed above bottom band by 23.3%. Bollinger Bands are 22% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.35 - 3.38 | 3.38 - 3.4 |
| Low: | 3.22 - 3.25 | 3.25 - 3.27 |
| Close: | 3.25 - 3.3 | 3.3 - 3.33 |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Fri, 19 Apr 2024
Inventiva S.A. (NASDAQ:IVA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Mon, 08 Apr 2024
Canaccord lifts Inventiva shares target on lanifibranor outlook - Investing.com
Mon, 01 Apr 2024
Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 28 Mar 2024
Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 27 Mar 2024
Inventiva SA ADR Announces Optimistic 2023 Results - TipRanks.com - TipRanks
Wed, 27 Mar 2024
Inventiva reports its 2023 full-year results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 1.405e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 106 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0185e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -288.5 % |
| Return on Assets (ttm) | -69.2 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 2.316e+007 % |
| Gross Profit (p.s.) | 7.6 |
| Sales Per Share | 669.53 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -82 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.1 |
| Dividend | 0 |
| Forward Dividend | 57580 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|